VE-cadherin Polyclonal antibody

VE-cadherin Polyclonal Antibody for FC, IHC, WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

Human and More (1)

Applications

WB, IHC, IF, FC, ELISA

Conjugate

Unconjugated

Cat no : 27956-1-AP

Synonyms

7B4, 7B4 antigen, Cadherin 5, CD144, CDH5, FLJ17376, Vascular endothelial cadherin, VE cadherin



Tested Applications

Positive WB detected inHUVEC cells, human placenta tissue
Positive IHC detected inhuman placenta tissue, human breast cancer tissue, human lung cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive FC detected inHUVEC cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:1000-1:4000
Immunohistochemistry (IHC)IHC : 1:100-1:400
Flow Cytometry (FC)FC : 0.40 ug per 10^6 cells in a 100 µl suspension
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

27956-1-AP targets VE-cadherin in WB, IHC, IF, FC, ELISA applications and shows reactivity with Human samples.

Tested Reactivity Human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen VE-cadherin fusion protein Ag27487
Full Name cadherin 5, type 2 (vascular endothelium)
Calculated Molecular Weight 88 kDa
Observed Molecular Weight120-140 kDa
GenBank Accession NumberNM_001795
Gene Symbol CDH5
Gene ID (NCBI) 1003
RRIDAB_2918136
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Cadherins are a family of transmembrane glycoproteins that mediate calcium-dependent cell-cell adhesion and play an important role in the maintenance of normal tissue architecture. Vascular endothelial cadherin (VE-cadherin), also known as Cadherin-5 (CDH5) or CD144, is a member of the type II classical cadherin family of cell adhesion proteins (PMID: 21269602). VE-cadherin is expressed specifically in endothelial cells and mediates homophilic adhesion in the vascular endothelium (PMID: 1522121; 8555485; 21269602). VE-cadherin plays a role in the organization of lateral endothelial junctions and in the control of permeability properties of vascular endothelium (PMID: 1522121). VE-cadherin has also been shown to be required for angiogenesis (PMID: 16473763; 18162609). The calculated molecular weight of VE-cadherin is 88 kDa and the apparent molecular weight of 120-140 kDa is higher due to post-translational glycosylation and phosphorylation (PMID: 10460833; 29894844). Full-length VE-cadherin can be proteolytically cleaved to generate a fragment of 90-100 kDa (PMID: 9786462; 22064597).

Protocols

Product Specific Protocols
WB protocol for VE-cadherin antibody 27956-1-APDownload protocol
IHC protocol for VE-cadherin antibody 27956-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
WB

Nat Commun

FNIP1 abrogation promotes functional revascularization of ischemic skeletal muscle by driving macrophage recruitment

Authors - Zongchao Sun
humanIF

Bioengineering (Basel)

Organotypic 3D Co-Culture of Human Pleura as a Novel In Vitro Model of Staphylococcus aureus Infection and Biofilm Development

Authors - Olga Kurow
WB

Front Cell Infect Microbiol

Analysis of miRNAs Involved in Mouse Heart Injury Upon Coxsackievirus A2 Infection.

Authors - Zhaoke Wu
humanIF

Bioengineering (Basel)

A Transwell-Based Vascularized Model to Investigate the Effect of Interstitial Flow on Vasculogenesis

Authors - Pengwei Deng
humanIF

J Hypertens

Short-chain acyl-CoA dehydrogenase is a potential target for the treatment of vascular remodelling

Authors - Xiaoyi Zhong
IF

Oral Dis

Artemisinin suppressed tumour growth and induced vascular normalisation in oral squamous cell carcinoma via inhibition of MIF

Authors - Xiang-Hua Yu